PM
CEMI

Precept Management’s Chembio diagnostics, Inc. CEMI Stock Holding History

Precept Management’s Portfolio CEMI Stock Details CEMI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-150,000
Closed -$713K – 71
2020
Q4 		$713K Buy
+150,000
New +$775K 0.29% 44

Other funds holding CEMI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PM
Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Precept Management's CEMI Position: Q1 2021 in Review

Precept Management sold out of Chembio diagnostics, Inc. (CEMI) in Q1 2021, closing a stake of 150,000 shares — an estimated $713K sold.

Precept Management first reported a position in CEMI in Q4 2020 and held it in 1 quarter. The position peaked at $713K in Q4 2020. 72 funds tracked by Wall St. Rank hold CEMI as of Q1 2021.

  • Precept Management reported no remaining Chembio diagnostics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Precept Management sold 150,000 Chembio diagnostics, Inc. shares in Q1 2021, an estimated $713K.
  • Precept Management first reported a position in Chembio diagnostics, Inc. in Q4 2020 and held it in 1 quarter.
  • Precept Management's Chembio diagnostics, Inc. position peaked at $713K in Q4 2020.
  • 72 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q1 2021.

Based on Precept Management's 13F filing for Q1 2021, filed 17 May 2021.